

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7312572

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
FERUZ KURBANOV	03/31/2022
RECEIVING PARTY DATA	
Name:	ROCHE MOLECULAR SYSTEMS, INC.
Street Address:	4300 HACIENDA DR.
City:	PLEASANTON
State/Country:	CALIFORNIA
Postal Code:	94588
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17274667
CORRESPONDENCE DATA	
Fax Number:	(925)225-1128
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	925-251-6721
Email:	stephanie.schulman@roche.com
Correspondent Name:	STEPHANIE SCHULMAN
Address Line 1:	4300 HACIENDA DR.
Address Line 4:	PLEASANTON, CALIFORNIA 94588
ATTORNEY DOCKET NUMBER:	P34971-US-1
NAME OF SUBMITTER:	ERIC GRANT LEE
SIGNATURE:	/Eric Grant Lee/
DATE SIGNED:	05/04/2022
Total Attachments: 3	
source=P34971-US-1 non prov assignment Inv to RMS_Signed#page1.tif	
source=P34971-US-1 non prov assignment Inv to RMS_Signed#page2.tif	
source=P34971-US-1 non prov assignment Inv to RMS_Signed#page3.tif	

P34971-US-1

ASSIGNMENT

We,

Feruz Kurbanov, a United States Citizen of Oakland, California, U.S.A.

(hereinafter "Assignors"), while employed by Roche Molecular Solutions, Inc., having a place of business at 4300 Hacienda Drive, Pleasanton, California 94588. U.S.A.

have invented one or more inventions which are at least as embodied in:

Roche Ref. No.	Country	Application Number	Application Date
P34971-US-1	U.S.A.	17/274,667	09.March.2021

Entitled: FORMAMIDE FREE TARGET ENRICHMENT COMPOSITIONS FOR NEXT-GENERATION SEQUENCING APPLICATIONS

which application is referred to herein as the "Patent Application" which claims priority to and the benefit of:

Roche Ref. No.	Country	Application Number	Application Date
P34971-US	U.S.A.	62/730,908	13 Sept 2018
P34971-WO	PCT	PCT/EP2019/074320	12 Sept 2019

collectively, the "Invention."

In consideration of our obligations and other valuable consideration constituting adequate and full compensation, we each hereby sell, assign, and transfer to Roche Molecular Solutions, Inc., its successors and assigns (collectively, "Assignee"), each of our respective full and exclusive right, title, and interest in the Invention, the Patent Application, and any corresponding patent rights throughout the United States and its territories and dependencies, and all other countries and jurisdictions of the world, or hereby acknowledge the previous transfer to Assignee of all such right, title and interest in the Invention, the Patent Application, and any corresponding patent rights throughout the United States and its territories and dependencies, and all other countries and jurisdictions of the world. The conveyance of patent rights includes, without limitation, full and exclusive right, title, and interest in all nonprovisional patent applications claiming all or part of the Invention and/or claiming the benefit of a filing date of the Patent Application, and any patents that may issue from any divisional, continuation, continuation-in-part, substitution, conversion, re-examination, reissue, renewal, prolongation or extension thereof; and the right to claim priority from the Patent Application as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law.

PAGE 1 OF 3

PATENT
REEL: 059809 FRAME: 0128

P34971-US-1

The Invention was made as a result of our activities at or on behalf of Assignee or as a result of our utilization of information, facilities or other resources of Assignee. The conditions under which the Invention was made are such as to entitle Assignee under the applicable law to each of our entire respective right, title, and interest in the Invention and any corresponding patent applications and/or patents in the United States and its territories and dependencies, and all other countries and jurisdictions of the world.

Assignors each authorize and request the issuance of any patents arising from nonprovisional patent applications claiming all or part of the Invention and/or claiming the benefit of a filing date of the Patent Application to the Assignee to be held as fully and entirely as the same would have been held by us had this assignment not been made.

Assignors each warrant that, to the best of their knowledge, there are no outstanding assignments, grants, liens, encumbrances, or agreements either written, oral, or implied that will impair, diminish, limit, or abridge the interest herein conveyed.

Assignors each also agree upon reasonable request to communicate with the Assignee, its representatives or agents, any facts known to us respecting all or part of the Invention, and testify in any legal proceedings, sign all lawful papers, execute all nonprovisional, divisional, continuation, continuation-in-part, re-examination, and reissue applications, make all rightful oaths, provide all requested documents, and do everything reasonably possible to aid the Assignee, its representatives or agents, to obtain and enforce proper patent protection for all or part of the Invention in the United States or any other country of the world. These provisions are binding upon each of our heirs, legal representatives, administrators and assigns.

This Assignment may be executed in one or more counterparts, each of which when executed and delivered, by facsimile or other electronic transmission, by mail delivery, or by other form of delivery, will be an original and all of which will constitute one and the same Assignment.

IN WITNESS WHEREOF, this Assignment is executed as of the date(s) indicated on the following counterpart signature page(s).

REMAINDER OF PAGE INTENTIONALLY BLANK

PAGE 2 OF 3

PATENT
REEL: 059809 FRAME: 0129

P34971-US-1

COUNTERPART SIGNATURE PAGE

Case No.	Country	Filing Date	Serial No.
P34971-US-1	United States		

Place: Mountain View, CA

Dated: 31-Mar-2022

ASSIGNOR:

DocuSigned by:

Feruz Kurbanov

2805FCE2758D4E3

Feruz Kurbanov

ASSIGNEE: Roche Molecular Solutions, Inc.

Place: Pleasanton, CA, USA

Dated: 04-21-22

Penelope C. Greene
HEAD OF INTELLECTUAL PROPERTY